Overview
Owlet Q3 revenue rises 44.6% yr/yr, beating analyst expectations
Adjusted EPS for Q3 beats consensus, reflecting strong operational performance
Company reports record Q3 net income of $4.1 mln, reversing a loss in Q3 2024
Outlook
Owlet expects full-year 2025 revenue between $103 mln and $106 mln
Company anticipates 2025 gross margins of 48% to 50%
Owlet projects 2025 adjusted EBITDA between $1.25 mln and $2 mln
Result Drivers
PRODUCT SALES - Increased sales of Dream Sock and Dream Duo products drove revenue growth
INTERNATIONAL EXPANSION - Strong international growth with 171% increase yr/yr, supported by new regulatory clearance in India
SUBSCRIPTION GROWTH - Owlet360 subscription surpasses 85,000 paying subscribers, expanding to international markets
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $32 mln | $27.18 mln (4 Analysts) |
Q3 Adjusted EPS | Beat | $0.03 | -$0.21 (2 Analysts) |
Q3 Adjusted EBITDA | Beat | $1.60 mln | $483,250 (4 Analysts) |
Q3 Gross Margin | 50.60% | ||
Q3 Gross Profit | $16.20 mln | ||
Q3 Operating Expenses | $15 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Owlet Inc is $13.00, about 15.4% above its November 12 closing price of $11.00
Press Release: ID:nBw2t1FJ1a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)